2025-04-29 21:37:09
Latest Post
UTI Asset Management Company Ltd Q4 FY25 consolidated net profit falls to Rs. 87.46 crores
Jindal Hotels Ltd Q4 FY2025 PAT declines to Rs. 41.49 lakhs
Bajaj Finserv Ltd Q4 FY2024-25 consolidated profit climbs to Rs. 2416.64 crores
CEAT Ltd posts consolidated Q4 FY25 PAT of Rs. 99.49 crores
Escorp Asset Management Ltd Q4 FY2025 net profit surges to Rs. 10.98 crores
Stock Report
Nectar Lifesciences Ltd posts consolidated PAT of Rs. 3.67 crore in Q4FY23
Posted On : 2023-05-26 22:32:30( TIMEZONE : IST )
Nectar Lifesciences Limited has reported Consolidated financial results for the period ended March 31, 2023.
Financial Results (Q4 FY2023) - QoQ Comparison
The company has reported total income of Rs. 406.7385 crores during the period ended March 31, 2023 as compared to Rs. 357.3655 crores during the period ended December 31, 2022.
The company has posted net profit / (loss) of Rs. 3.6768 crores for the period ended March 31, 2023 as against net profit / (loss) of Rs. -9.2873 crores for the period ended December 31, 2022.
The company has reported EPS of Rs. 0.16 for the period ended March 31, 2023 as compared to Rs. -0.41 for the period ended December 31, 2022.
| Financials | Q4 FY2023 | Q3 FY2023 | % Change |
| Total Income | ₹406.7385 crs | ₹357.3655 crs |  13.82% |
| Net Profit | ₹3.6768 crs | ₹-9.2873 crs | 139.59% |
| EPS | ₹0.16 | ₹-0.41 | 139.02% |
Financial Results (Q4 FY2023) - YoY Comparison
The company has reported total income of Rs.406.7385 crores during the period ended March 31, 2023 as compared to Rs.476.7533 crores during the period ended March 31, 2022.
The company has posted net profit / (loss) of Rs.3.6768 crores for the period ended March 31, 2023 as against net profit / (loss) of Rs.11.66 crores for the period ended March 31, 2022.
The company has reported EPS of Rs.0.16 for the period ended March 31, 2023 as compared to Rs.0.52 for the period ended March 31, 2022.
| Financials | Q4 FY2023 | Q4 FY2022 | % Change |
| Total Income | ₹406.7385 crs | ₹476.7533 crs |  -14.69% |
| Net Profit | ₹3.6768 crs | ₹11.66 crs | -68.47% |
| EPS | ₹0.16 | ₹0.52 | -69.23% |
Financial Results (Year Ended FY2023) - YoY Comparison
The company has reported total income of Rs.1566.8482 crores during the Financial Year ended March 31, 2023 as compared to Rs.1680.15 crores during the Financial Year ended March 31, 2022.
The company has posted net profit / (loss) of Rs.-24.1829 crores for the Financial Year ended March 31, 2023 as against net profit / (loss) of Rs.25.0467 crores for the Financial Year ended March 31, 2022.
The company has reported EPS of Rs.-1.08 for the Financial Year ended March 31, 2023 as compared to Rs.1.12 for the Financial Year ended March 31, 2022.
| Financials | Year Ended FY2023 | Year Ended FY2022 | % Change |
| Total Income | ₹1566.8482 crs | ₹1680.15 crs | -6.74% |
| Net Profit | ₹-24.1829 crs | ₹25.0467 crs | -196.55% |
| EPS | ₹-1.08 | ₹1.12 | -196.43% |
Shares of Nectar Lifesciences Limited was last trading in BSE at Rs. 16.74 as compared to the previous close of Rs. 16.70. The total number of shares traded during the day was 10361 in over 119 trades.
The stock hit an intraday high of Rs. 16.99 and intraday low of 16.50. The net turnover during the day was Rs. 173279.00.
